Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 5 |
| 1.1 List of Tables | 5 | 1 |
| 1.2 List of Figures | 6 | 2 |
| 2 Sales Force Effectiveness in the Pharmaceutical Industry Introduction | 8 | 2 |
| 2.1 GBI Research Report Guidance | 9 | 1 |
| 3 The Need for Sales Force Effectiveness | 10 | 7 |
| 3.1 Introduction | 10 | 1 |
| 3.1.1 Shift in product portfolio | 10 | 1 |
| 3.1.2 Regulatory Tightening | 11 | 1 |
| 3.1.3 Specialty care focus | 12 | 1 |
| 3.1.4 Shift of power | 12 | 1 |
| 3.1.5 Industry consolidation | 12 | 1 |
| 3.1.6 Non-personal promotion | 12 | 1 |
| 3.1.7 R&D Costs Increase against Revenue Growth for the Top 10 Pharmaceutical Companies | 13 | 2 |
| 3.1.8 Layoff in the Pharmaceutical Companies | 15 | 1 |
| 3.1.9 Shrinking Field Force Model | 16 | 1 |
| 4 Sales Force Sizing | 17 | 5 |
| 4.1 Introduction | 17 | 1 |
| 4.2 Affordability | 17 | 1 |
| 4.3 Workload build-up | 17 | 1 |
| 4.3.1 Case 1 | 18 | 1 |
| 4.3.2 Case 2 | 19 | 1 |
| 4.4 Competitive Benchmarking | 19 | 1 |
| 4.5 Promotion Response Modeling | 20 | 2 |
| 5 Sales Force Recruitment | 22 | 8 |
| 5.1 Introduction | 22 | 1 |
| 5.2 Sales Force Recruitment Strategy | 22 | 1 |
| 5.2.1 Recruiting Strategy | 23 | 1 |
| 5.2.2 Business Objectives | 23 | 1 |
| 5.2.3 Identify the specific metrics that will define success | 23 | 1 |
| 5.2.4 Define Job Requirements | 24 | 1 |
| 5.2.4.1 Define work requirements | 24 | 1 |
| 5.2.4.2 Define Key worker Competencies | 24 | 1 |
| 5.2.5 Establishing Assessment Validity | 24 | 1 |
| 5.2.6 Implementation | 24 | 1 |
| 5.3 Recruitment/Employment Process Outsourcing | 25 | 1 |
| 5.3.1 Case Studies | 25 | 1 |
| 5.3.1.1 An International Pharmaceutical Company and its RPO | 25 | 1 |
| 5.3.1.2 AstraZeneca &RPO | 26 | 2 |
| 5.4 The Diversity and Inclusion Imperative from Novartis | 28 | 1 |
| 5.4.1 Improving Representation | 29 | 1 |
| 5.4.2 Building Capability | 29 | 1 |
| 5.4.3 Driving Ownership and Accountability | 29 | 1 |
| 5.4.4 Ensuring Sustainability | 29 | 1 |
| 6 Sales Force Training &Compensation | 30 | 10 |
| 6.1 Introduction | 30 | 1 |
| 6.2 Models | 30 | 1 |
| 6.2.1 Survey on Sales Force Training | 30 | 1 |
| 6.3 Specialty Care Training | 31 | 1 |
| 6.3.1 Sanofi Aventis and their Specialty Care Training | 31 | 1 |
| 6.3.1.1 Selling approach and it Adoption | 31 | 1 |
| 6.3.1.2 Effectiveness in the Hospital Market | 31 | 1 |
| 6.3.1.3 Accountability Culture | 31 | 1 |
| 6.3.1.4 Skill Development for Hospital Market | 32 | 1 |
| 6.3.1.5 Skills and Fine-Tuning | 32 | 1 |
| 6.3.1.6 Understanding the Value | 32 | 1 |
| 6.3.2 Continuous Assessments | 33 | 1 |
| 6.4 Leaders Take the Initiative | 33 | 1 |
| 6.4.1 Five Step Model | 34 | 1 |
| 6.4.1.1 Pinpoint | 34 | 1 |
| 6.4.1.3 Feedback | 34 | 1 |
| 6.4.1.4 Reinforce | 34 | 1 |
| 6.4.1.5 Evaluate | 34 | 1 |
| 6.4.2 Impact of Behavioral Coaching | 34 | 3 |
| 6.5 Tailored Incentive Management | 37 | 1 |
| 6.5.1 Plan authoring and simulation | 38 | 1 |
| 6.5.2 Schema Calculation | 38 | 1 |
| 6.5.3 Credit Allocation and Payment | 38 | 1 |
| 6.5.4 Reporting &Analysis | 38 | 2 |
| 7 Sales Models | 40 | 37 |
| Introduction | 40 | 1 |
| 7.2 Key account Management | 41 | 1 |
| 7.2.1 Introduction | 41 | 1 |
| 7.2.2 Key Account Management Process | 41 | 1 |
| 7.2.2.1 Key Account Identification and Prioritization | 42 | 3 |
| 7.2.2.2 Understanding needs and developing customer insights | 45 | 1 |
| 7.2.2.3 Forming the virtual account team | 45 | 1 |
| 7.2.2.4 Developing the strategic plan | 46 | 1 |
| 7.2.2.5 Communicating and implementing the plan | 46 | 1 |
| 7.2.2.6 Reviewing the results | 47 | 1 |
| 7.2.3 Types of Key Account Management | 47 | 1 |
| 7.2.3.1 Target Account Selling | 47 | 1 |
| 7.2.3.2 Orchestrated Account Selling | 47 | 1 |
| 7.2.3.3 Co-development Partnerships | 47 | 1 |
| 7.2.4 Case Studies | 48 | 1 |
| 7.2.4.1 Lundbeck in UK and its Success | 48 | 1 |
| 7.2.4.2 Abbott Laboratories Sales Force Optimization | 49 | 6 |
| 7.3 Contract Sales Outsourcing | 55 | 1 |
| 7.3.1 Contract Sales Representatives | 56 | 1 |
| 7.3.2 Sales Team Recruitment and Training | 56 | 1 |
| 7.3.3 Sales Data Analytics and Management | 57 | 1 |
| 7.3.4 Shared Sales Teams and Telesales | 57 | 1 |
| 7.3.5 Medical Science Liaisons | 57 | 1 |
| 7.3.6 The Evolving Model | 58 | 1 |
| 7.3.7 Case Study | 59 | 1 |
| 7.3.7.1 Quintiles the UK based Biotechnology Company | 59 | 1 |
| 7.4 Closed Loop Marketing | 60 | 1 |
| 7.4.1 Benefits for Sales &Physicians | 61 | 1 |
| 7.4.2 Benefits for Analytics | 61 | 1 |
| 7.4.3 Benefits for Legal &Regulatory Departments | 61 | 1 |
| 7.4.4 Benefits for Marketing | 61 | 1 |
| 7.4.5 Case Studies | 61 | 1 |
| 7.4.5.1 Wyeth and Closed Loop Marketing | 61 | 4 |
| 7.5 Examining Strategies | 65 | 1 |
| 7.5.1 Promotional Response Model | 66 | 1 |
| 7.6 Survey on Sales and Marketing Strategies | 67 | 4 |
| 7.7 Sales Force Effectiveness Dashboards | 71 | 1 |
| 7.8 Investment Priorities | 72 | 1 |
| 7.9 New Sales Strategies Implemented | 73 | 1 |
| 7.10 The Future Strategies to be Implemented | 74 | 3 |
| 8 Sales Force Effectiveness Efficiency Analysis | 77 | 40 |
| 8.1 Eli Lilly and Company | 81 | 1 |
| 8.1.1 Overview | 81 | 1 |
| 8.1.2 SG&A and R&D Spending | 82 | 1 |
| 8.1.3 SG&A Analysis | 83 | 1 |
| 8.2 Johnson &Johnson | 84 | 1 |
| 8.2.1 Overview | 84 | 1 |
| 8.2.2 SG&A and R&D Spending | 85 | 1 |
| 8.2.3 SG&A Analysis | 86 | 1 |
| 8.3 Pfizer, Inc. | 87 | 1 |
| 8.3.1 Overview | 87 | 1 |
| 8.3.2 SG&A and R&D Spending | 88 | 1 |
| 8.3.3 SG&A Analysis | 89 | 1 |
| 8.4 Merck &Co Inc | 90 | 1 |
| 8.4.1 Overview | 90 | 1 |
| 8.4.2 SGA and R&D Spending | 91 | 1 |
| 8.4.3 SG&A Analysis | 92 | 1 |
| 8.5 Sanofi-Aventis | 93 | 1 |
| 8.5.1 Overview | 93 | 1 |
| 8.5.2 SGA and R&D Spending | 94 | 1 |
| 8.5.3 SG&A Analysis | 95 | 1 |
| 8.6 Bristol-Myers Squibb | 96 | 1 |
| 8.6.1 Overview | 96 | 1 |
| 8.6.2 SGA and R&D Spending | 97 | 1 |
| 8.6.3 SG&A Analysis | 98 | 1 |
| 8.7 GlaxoSmithKline | 99 | 1 |
| 8.7.1 Overview | 99 | 1 |
| 8.7.2 SGA and R&D Spending | 100 | 1 |
| 8.7.3 SG&A Analysis | 101 | 1 |
| 8.8 Novo Nordisk | 102 | 1 |
| 8.8.1 Overview | 102 | 1 |
| 8.8.2 SGA vs. R&D Spending | 103 | 1 |
| 8.8.3 SG&A Analysis | 104 | 1 |
| 8.9 Allergan Inc. | 105 | 1 |
| 8.9.1 Overview | 105 | 1 |
| 8.9.2 SGA and R&D Spending | 105 | 1 |
| 8.9.3 SG&A Analysis | 106 | 1 |
| 8.10 Abbott Laboratories | 107 | 1 |
| 8.10.1 Overview | 107 | 1 |
| 8.10.2 SGA and R&D Spending | 108 | 1 |
| 8.10.3 SG&A Analysis | 109 | 1 |
| 8.11 Genzyme Corporation | 110 | 1 |
| 8.11.1 Company Overview | 110 | 1 |
| 8.11.2 Business Description | 110 | 1 |
| 8.11.3 SGA and R&D Spending | 111 | 1 |
| 8.11.4 SG&A Analysis | 112 | 1 |
| 8.12 Teva Pharmaceuticals | 113 | 1 |
| 8.12.1 Overview | 113 | 1 |
| 8.12.2 SGA and R&D Spending | 113 | 1 |
| 8.12.3 SG&A Analysis | 114 | 1 |
| 8.13 Astrazeneca | 115 | 1 |
| 8.13.1 Overview | 115 | 1 |
| 8.13.2 SGA and R&D Spending | 115 | 1 |
| 8.13.3 SG&A Analysis | 116 | 1 |
| 9 Sales Force Effectiveness in the Pharmaceutical Industry Appendix | 117 | 4 |
| 9.1 Market Definitions | 117 | 1 |
| 9.2 Abbreviations | 117 | 1 |
| 9.3 Research Methodology | 118 | 2 |
| 9.3.1 Coverage | 118 | 1 |
| 9.3.2 Secondary Research | 119 | 1 |
| 9.3.3 Primary Research | 119 | 1 |
| 9.3.4 Expert Panel Validation | 119 | 1 |
| 9.4 Contact Us | 120 | 1 |
| 9.5 Disclaimer | 120 | 1 |
| 9.6 Sources | 120 | 1 |